United States Pharmacopeia CEO salary and executive pay
United States Pharmacopeia paid its CEO, Ronald T Piervincenzi, $1,104,534 for the fiscal year ending June 2025. That is down $50,628 (4.4%) from the fiscal year ending June 2024. Total revenue on that return was $357,720,644, up 1.1% from $353,749,327 for the fiscal year ending June 2024. United States Pharmacopeia ranks 11th of 12 health organizations on this site by CEO pay. United States Pharmacopeia has 3 Form 990 returns on record, for fiscal years ending 2023 to 2025.
Last updated from IRS e-file data. EIN 13-1656692, Rockville, MD.
CEO, fiscal year ending June 2025
$1,104,534
- Total revenue
- $357,720,644
- CEO pay vs. peers
- Higher than 36%
Source: Form 990, fiscal year ending June 2025, IRS object ID 202513179349305956.View the filing
Peers: the 207 other organizations on this site with revenue of $50 million to $500 million. Ranked 132nd of 208 by top pay as a share of revenue. Pay is 0.31% of revenue, our calculation from the same return. Revenue is Part I, line 12; peers are compared on their latest full-year returns.
Highest-paid people on the latest return
On the latest return, 9 people were paid more than $500,000, 1 of them more than $1 million.
| Name and title | Total |
|---|---|
| Ronald T Piervincenzi CEO CHIEF EXECUTIVE OFFICER & EX-OFFICIO | $1,104,534 |
| Jakob Venema To 625EVP & CHIEF SCIENCE OFFICER | $708,056 |
| Anthony P LakavageSECRETARY & SVP GLBL EA | $628,264 |
| John A Giannone To 824VP, COMPENDIAL OPERATIONS | $610,709 |
| Amanda D CowleySVP, LEGAL, STRATEGY & PEOPLE | $608,543 |
Also paid on the latest return: Stanley D Burhans (CHIEF FINANCIAL OFFICER), $589,532; Emily M Kaine (SVP, GBL HEALTH & MANUFACTURING SVCS), $579,612; Venkat Surendra Nath Koduru (SVP REGIONS & PROGRAM OPS.(TO 6/25)), $528,358; Debra J Perez (CHIEF EQUITY OFFICER), $518,756; Michael S Levy (SVP, DIGITAL & INNOVATION), $486,751; Bruk Alemayehu (SVP, GLOBAL LAB & TECHNICAL OPS), $482,723; Fouad Atouf (SVP, SCI-GLOB BIO), $476,218; Jennifer Devine (SVP, DOC STDS & COMP POLICY), $450,937.
Also listed in Part VII of the latest return, with no pay reported: Dennis E Doherty MD (CONVENTION PRESIDENT), Todd K Abraham PhD MBA (TREASURER), Gregory E Amidon PhD (PHARMACEUTICAL SCIENCES TRUSTEE), Gwen Darien (PUBLIC TRUSTEE), Richard J Gilfillan MD MBA (AT LARGE TRUSTEE), Jesse L Goodman MD MPH (MEDICAL SCIENCES TRUSTEE), Laura Herman MBA MA (AT LARGE TRUSTEE), Thomas Menighan Bspharmmba (AT LARGE TRUSTEE), Krishna Reddy Nallamalla MD (AT LARGE TRUSTEE), Stephen Ostroff MD (MEDICAL SCIENCES TRUSTEE), Julio Sanchez Y Tepoz Mscsjd (AT LARGE TRUSTEE), John Taylor JD (AT LARGE TRUSTEE), Susan Winckler Rph JD (CHAIR AND PHARMA SCI TRUSTEE).
CEO pay by year
Each row is the CEO on that year's return.
| Fiscal year ending | Name and title | Total | Revenue | Source |
|---|---|---|---|---|
| Jun 2025 | Ronald T Piervincenzi CEO CHIEF EXECUTIVE OFFICER & EX-OFFICIO | $1,104,534 | $357,720,644 | Filing |
| Jun 2024 | Ronald T Piervincenzi CEO CHIEF EXECUTIVE OFFICER & EX-OFFICIO | $1,155,162 | $353,749,327 | Filing |
| Jun 2023 | Ronald T Piervincenzi CEO CHIEF EXECUTIVE OFFICER & EX-OFFICIO | $1,000,049 | $346,271,530 | Filing |
How this pay was reported
The parts of each total, as reported on the return for the fiscal year ending June 2025.
Source: Form 990, fiscal year ending June 2025, IRS object ID 202513179349305956.View the filing
| Part VII | Schedule J | |||||||
|---|---|---|---|---|---|---|---|---|
| Name and title | From org | Other | Base | Bonus | Other | Deferred | Nontaxable | Total |
| Ronald T PiervincenziCHIEF EXECUTIVE OFFICER & EX-OFFICIO | $975,149 | $129,385 | $760,961 | $188,946 | $25,242 | $117,452 | $11,933 | $1,104,534 |
| Jakob Venema To 625EVP & CHIEF SCIENCE OFFICER | $618,546 | $89,510 | $483,831 | $108,393 | $26,322 | $75,817 | $13,693 | $708,056 |
| Anthony P LakavageSECRETARY & SVP GLBL EA | $545,170 | $83,094 | $403,592 | $115,411 | $26,167 | $74,100 | $8,994 | $628,264 |
| John A Giannone To 824VP, COMPENDIAL OPERATIONS | $552,057 | $58,652 | $173,110 | $64,616 | $314,331 | $53,500 | $5,152 | $610,709 |
| Amanda D CowleySVP, LEGAL, STRATEGY & PEOPLE | $530,651 | $77,892 | $401,705 | $103,636 | $25,310 | $65,561 | $12,331 | $608,543 |
These figures come from United States Pharmacopeia's Form 990 returns, as the IRS publishes them. The methodology page explains how they're chosen. To report an error, email corrections@ceopaycheck.com.
How United States Pharmacopeia compares
Ranked 11th of 12 health organizations by CEO pay.
- Previous in this ranking: 10th, American Board of Internal Medicine, $1,566,325
- Next in this ranking: 12th, AIDS Healthcare Foundation, $668,273
Closest in revenue among organizations in the same revenue band:
San Francisco Foundation$670,879 (CEO), fiscal year ending Jun 2025
Blood Cancer United$930,517 (CEO), fiscal year ending Jun 2025
Cystic Fibrosis Foundation$1,275,151 (CEO), fiscal year ending Dec 2024
NPR$697,251 (CEO), fiscal year ending Sep 2025
Habitat for Humanity$592,703 (CEO), fiscal year ending Jun 2025
Common questions
Ronald T Piervincenzi (CHIEF EXECUTIVE OFFICER & EX-OFFICIO) was paid $1,104,534 for the fiscal year ending June 2025: $975,149 from United States Pharmacopeia and $129,385 in other compensation (Part VII columns D and F).
The CEO, Ronald T Piervincenzi, was the highest-paid person on the latest return, at $1,104,534.
United States Pharmacopeia paid its CEO, Ronald T Piervincenzi, $1,104,534 for the fiscal year ending June 2025. That is down $50,628 (4.4%) from the fiscal year ending June 2024. The earliest return on record is for the fiscal year ending June 2023, when the CEO was Ronald T Piervincenzi, paid $1,000,049. By fiscal year end: June 2023, $1,000,049 (Ronald T Piervincenzi); June 2024, $1,155,162; June 2025, $1,104,534.
United States Pharmacopeia's return for the fiscal year ending June 2025 reports total expenses of $333,614,948 and total revenue of $357,720,644 (Part I, lines 18 and 12), so revenue exceeded expenses by $24,105,696. Expenses were $330,337,653 for the fiscal year ending June 2024, so they rose 1.0%. The CEO's pay of $1,104,534 equals 0.33% of expenses, our calculation.
From the 3 Form 990 returns United States Pharmacopeia filed with the IRS for fiscal years ending 2023 to 2025. The latest full-year return was filed on November 13, 2025. Schedule J of the fiscal year ending June 2025 return breaks down pay for all 5 people in the pay breakdown above.